When Was Mounjaro Approved for Weight Loss?

Last reviewed: July 14, 2026

Last updated: July 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, gained FDA clearance for weight loss on November 8, 2023, following breakthrough clinical trial results showing average weight reductions of 20.7% in adults with obesity. This dual GLP-1 and GIP receptor agonist represents a significant advancement over single-mechanism weight loss medications. PlexusDx provides access to compounded tirzepatide injection at affordable pricing without insurance requirements.

The FDA Approval Timeline for Tirzepatide Weight Loss

The Food and Drug Administration approved Mounjaro (tirzepatide) for chronic weight management on November 8, 2023, marking a watershed moment in obesity treatment. This approval was based on data from the SURMOUNT clinical trials, which enrolled thousands of participants with obesity or overweight conditions and at least one weight-related comorbidity. The decision followed an accelerated review process that recognized the medication's potential to address a major public health challenge.

Prior to this 2023 authorization, tirzepatide had been available exclusively for type 2 diabetes management since its initial FDA approval in 2022. The expansion to weight loss indications opened the medication to a broader patient population seeking medically supervised weight reduction. This timeline compressed research and regulatory pathways, reflecting the urgent clinical need for effective obesity interventions.

How Tirzepatide Delivers Superior Weight Loss Results

Tirzepatide activates two distinct hormone pathways simultaneously: the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-action mechanism increases satiety signals to the brain, slows gastric emptying, and improves insulin secretion, creating multiple pathways to weight reduction. Clinical studies demonstrated that participants achieved average weight losses ranging from 16% to 20.7% depending on the dose used over 68 weeks of treatment.

The SURMOUNT-1 trial showed that 85% of tirzepatide-treated participants achieved at least 5% weight loss, compared to 35% in the placebo group. Higher doses produced more substantial results, with some participants losing more than 25% of their initial body weight. These outcomes significantly exceeded historical results from single-action GLP-1 medications like semaglutide, establishing tirzepatide as a benchmark-setting therapy.

Compounded Tirzepatide Versus Brand-Name Mounjaro

Brand-name Mounjaro typically costs between $900 and $1,300 per month without insurance coverage, making it financially inaccessible for many patients seeking weight loss treatment. PlexusDx offers compounded tirzepatide injection prepared by licensed 503A compounding pharmacies, starting at just $289 per month, eliminating the need for insurance authorization or membership fees. The compounded version contains identical active pharmaceutical ingredients to the brand product but provides substantial cost savings.

Compounded medications from 503A pharmacies must meet the same pharmaceutical quality standards as brand-name drugs, including sterility, strength, and purity requirements. PlexusDx sources compounded tirzepatide exclusively from licensed facilities, ensuring patients receive pharmaceutical-grade therapy without the brand markup. This approach democratizes access to tirzepatide for patients nationwide without compromising safety or efficacy.

Personalized Tirzepatide Therapy With Genetic Testing

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone), which analyzes how genetic variants influence your response to tirzepatide and related therapies. This peptide-pathway genetic assessment examines 14 distinct metabolic pathways, including key variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), FTO gene (rs9939609), and MC4R gene (rs17782313). Understanding these genetic predispositions helps guide optimal medication selection and dosing strategies tailored to your biology.

The Precision Peptide Genetic Test maps 49 specific peptide responses and provides over 150 personalized insights into your weight loss mechanism. This information allows PlexusDx healthcare providers to recommend whether tirzepatide injection, oral tirzepatide, semaglutide, or dual-compound therapies align best with your genetic weight-loss profile. Genetic-guided selection increases the likelihood of achieving meaningful, sustained weight reduction.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Exactly when did the FDA approve Mounjaro for weight loss?

The FDA approved Mounjaro (tirzepatide) for chronic weight management on November 8, 2023. This approval was based on data from the SURMOUNT clinical trial program, which demonstrated average weight losses of 20.7% in participants treated with tirzepatide over 68 weeks.

How much weight do most people lose on tirzepatide?

In the SURMOUNT-1 clinical trial, 85% of tirzepatide-treated participants achieved at least 5% weight loss, with average reductions of 16% to 20.7% depending on the dose. Some participants achieved weight losses exceeding 25% of their starting body weight, representing significantly greater results than single-action GLP-1 medications.

Why is PlexusDx tirzepatide so much cheaper than Mounjaro?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) through licensed 503A pharmacies, compared to $900–$1,300 for brand Mounjaro, because compounded medications eliminate brand manufacturing and marketing overhead. Your dose may need to go up, but your price won't—PlexusDx maintains flat monthly pricing across all commitment tiers, and no insurance or membership is required.

Are there safety concerns with compounded tirzepatide?

Compounded tirzepatide from licensed 503A pharmacies meets identical pharmaceutical quality, sterility, and purity standards as brand medications. PlexusDx sources exclusively from regulated compounding facilities, and treatment is supervised by licensed healthcare providers who monitor your response and adjust therapy as needed.

How does the Precision Peptide Genetic Test improve my tirzepatide results?

The Precision Peptide Genetic Test ($99 add-on) analyzes 49 peptides and 150+ genetic insights across 14 pathways, including variants in GLP1R, GIPR, FTO, and MC4R genes. This helps your PlexusDx provider determine whether tirzepatide injection, oral tirzepatide, semaglutide, or dual-compound therapy best matches your genetic weight-loss profile for maximum effectiveness.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Weight Loss Injections Mounjaro

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.